Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. It offers HD-X instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids. The company also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assay kits and other consumables such as reagents. In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.

Quanterix Corporation

Quanterix is a company that is digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s ultra-sensitive detection solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the role of biomarkers in the continuum of  health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognosis and precise treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts.

Alzheimer's Drug Discovery Foundation

bioMerieux

In-Q-Tel

ARCH Venture Partners

T. Rowe Price

Cormorant Asset Management

Hercules Capital

Trinitas Capital

Tufts University

ARCH Overage Fund

Bain Capital Ventures

Quanterix

The inaccessibility of inexpensive and noninvasive Alzheimer’s diagnostics has left 50-70% of symptomatic AD patients without a correct and timely diagnosis, impacting quality of life, medical autonomy, and general wellbeing.

Currently, clinicians diagnose AD using a combination of symptom presentation, brain imaging, and the detection of CSF biomarkers for AD. Despite their effectiveness, they are often invasive and costly, making them unsuitable for most primary and secondary care settings, but blood-based biomarkers may offer a new path. There is substantial evidence supporting the utility of blood biomarkers for AD diagnosis, particularly diagnosing early-stage AD, prior to cognitive symptom presentation. https://bit.ly/3TcfGT6

#AlzheimersDisease #Biomarkers #CSF

Clinicians use various biomarkers to diagnose, track, and treat disease, and new biomarkers or improving the sensitivity of existing biomarkers could fulfill unmet clinical needs and improve patient outcomes. Blood-based markers like NfL, p-Tau 181, p-Tau 217, and GFAP are already playing a critical role in advancing patient care for disorders like Alzheimer’s and Parkinson’s. https://bit.ly/3RilsA9

The Scientist #Biomarkers #Alzheimers #BloodTest

A team from Wyss Institute at Harvard University, Massachusetts Institute of Technology, and Brigham and Women's Hospital in Boston demonstrated the use of microneedles and ultra-sensitive Simoa measurements to monitor protein biomarkers in responses to a combination immunotherapy against melanoma.

Learn more about the study and Simoa’s pivotal role: https://bit.ly/44rlF8I

Quanterix invites you to delve into the forefront of neurology laboratory medicine. Our recent Nature Portfolio webinar, featuring Dr. Cheryl Wellington from the The University of British Columbia, explores the transformative role of ultrasensitive immunoassays in researching blood biomarkers for neurological indications. From traumatic brain injuries to neurodegenerative diseases, this webinar is a valuable resource for those passionate about advancing neurological research. Access the recording here: https://bit.ly/47IKRcK 🧠 

#NeurologyLabMedicine #WebinarRecording

COM:QUANTERIX